TRUMAB 150MG INJ VIAL

About

TRUMAB 150MG INJ VIAL contains Trastuzumab, a recombinant humanized monoclonal antibody that specifically targets the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a protein found on the surface of some cancer cells, and its overexpression can lead to aggressive tumor growth and proliferation. Trastuzumab works by binding to the extracellular domain of the HER2 receptor, thereby inhibiting downstream signaling pathways that promote cell growth and survival. This action not only directly inhibits cancer cell proliferation but also marks HER2-positive cancer cells for destruction by the body's immune system through antibody-dependent cell-mediated cytotoxicity (ADCC).

This targeted therapy is a cornerstone in the treatment of HER2-positive cancers, significantly improving patient outcomes by reducing tumor size, preventing recurrence, and extending survival. It is typically used in combination with chemotherapy or as a single agent, depending on the stage and type of cancer. Before initiating treatment, patients are tested for HER2 overexpression to ensure that the therapy will be effective. Trastuzumab represents a major advancement in personalized cancer medicine, offering a highly specific and effective treatment option for a subset of aggressive cancers.

Uses

• HER2-positive early breast cancer (adjuvant)
• HER2-positive metastatic breast cancer
• HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma
• HER2-positive low-risk ductal carcinoma in situ (off-label)

Directions For Use

Administered intravenously by a healthcare professional, typically as an infusion over a specified duration.

Benefits

• Significantly improves survival in HER2-positive cancers
• Reduces the risk of cancer recurrence
• Effective in both early and metastatic disease settings
• Targeted therapy with specific action on cancer cells
• Often used in combination with chemotherapy for enhanced efficacy
• Well-established efficacy and safety profile

Side Effects

• Infusion-related reactions (fever, chills, pain)
• Cardiotoxicity (heart failure, decreased ejection fraction)
• Nausea
• Diarrhea
• Headache
• Asthenia (weakness)
• Neutropenia
• Anemia
• Rash
• Cough
• Dyspnea (shortness of breath)
• Myalgia (muscle pain)

Safety Measures

• Alcohol - No specific interaction with alcohol; however, general health advice applies during cancer treatment.
• Pregnancy - Contraindicated; can cause fetal harm. Effective contraception must be used during and for 7 months after treatment.
• Breastfeeding - Not recommended as it is unknown if Trastuzumab is excreted in human milk. Consult your doctor.
• Liver - Use with caution in patients with pre-existing liver conditions; monitor liver function during treatment.
• Kidney - Use with caution in patients with pre-existing kidney conditions; monitor renal function during treatment.
• Lung - Use with caution in patients with pre-existing lung conditions; monitor for pulmonary toxicity, including interstitial lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.